Skip to main content

Table 4 The mean percentage HRQoL scores estimated for the study

From: Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

QoL score tested

Mean (SD)

Global health status

69 · 29 (22 · 75)

Functional scales

Physical functioning

85 · 01 (19 · 66)

Role functioning

73 · 46 (31 · 44)

Emotional functioning

83 · 02 (21 · 40)

Cognitive functioning

83 · 41 (19 · 97)

Social functioning

77 · 29 (27 · 31)

Cancer Symptoms

Fatigue

27 · 19 (26 · 32)

Nausea & vomiting

3 · 55 (12 · 87)

Pain

14 · 90 (23 · 43)

Dyspnoea

9 · 67 (20 · 76)

Insomnia

22 · 60 (28 · 03)

Appetite loss

7 · 59 (18 · 14)

Constipation

17 · 82 (26 · 63)

Diarrhoea

12 · 31 (23 · 60)

Financial difficulties

9 · 91 (21 · 49)

Prostate cancer specific symptoms

Urinary symptoms

28 · 28 (19 · 72)

Bowel symptoms

9 · 00 (14 · 15)

Hormone treatment-related symptoms

16 · 57 (16 · 59)

Sexual interest

36 · 88 (28 · 48)

Depression anxiety and stress symptoms

Depression

4 · 50 (7 · 49)

Anxiety

2 · 89 (4 · 58)

Stress

5 · 54 (7 · 52)